These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including risks relating to the occurrence of adverse safety events, restrictions on use with Biogen’s products or product liability claims; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; results in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; problems with Biogen’s manufacturing processes or capacity; failure to comply with legal and regulatory requirements; environmental risks; third party collaboration risks and the other risks identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission.